What is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that drives pulsatile secretion of growth hormone (GH) from anterior pituitary somatotroph cells. Native GHRH is a 44-amino-acid peptide that is rapidly cleaved in circulation by dipeptidyl peptidase IV (DPP-IV), giving it a plasma half-life of only a few minutes in physiological systems. CJC-1295 was developed to address this stability limitation through two key structural modifications: truncation to the biologically essential first 29 amino acids of GHRH (corresponding to the active fragment also found in sermorelin) and the addition of a maleimido-propionamide (MPA) reactive group at the C-terminal lysine residue.
It is this MPA reactive group — the structural basis of what is called the Drug Affinity Complex, or DAC — that distinguishes CJC-1295 from simpler GHRH analogues and makes it one of the most studied extended-action GHRH analogues in preclinical research.
The Drug Affinity Complex: Mechanism of Albumin Binding
The DAC technology underlying CJC-1295's extended half-life operates through a bioconjugation reaction between the peptide's reactive MPA group and the free thiol (-SH) of the single unpaired cysteine residue (Cys-34) on serum albumin. This reaction — a thiol-maleimide Michael addition — forms a stable covalent thioether bond between the peptide and the albumin molecule.
Serum albumin is the most abundant plasma protein, with a molecular weight of approximately 66 kDa and a plasma half-life of approximately 19 days in rodent models and longer in larger animals. Once covalently conjugated to albumin, CJC-1295 acquires albumin's pharmacokinetic characteristics: it is protected from renal filtration (due to albumin's size exceeding the glomerular filtration threshold) and from proteolytic degradation, and it benefits from the neonatal Fc receptor (FcRn) recycling mechanism that returns albumin to circulation after endosomal uptake.
The result is a GHRH analogue with a dramatically extended effective half-life compared to native GHRH or shorter GHRH analogues such as sermorelin. In research models, this translates from a half-life measured in minutes for native GHRH to a half-life measured in days for CJC-1295 (DAC). The DAC-conjugated fraction can be released from albumin under reducing conditions or gradually through hydrolysis, allowing for sustained but not entirely permanent receptor engagement.
GHRH Receptor Signaling in Pituitary Cell Models
Regardless of the DAC extension, CJC-1295 acts at the GHRH receptor (GHRHR) — a class B GPCR expressed primarily on anterior pituitary somatotroph cells. Receptor engagement activates adenylyl cyclase via Gs protein coupling, raising intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP response element-binding protein), ultimately driving GH gene expression and promoting GH secretory granule formation in somatotrophs.
In short-term stimulation assays using primary pituitary cells or the GH3 pituitary cell line, CJC-1295 produces concentration-dependent GH release consistent with GHRHR agonism. The EC50 values for CJC-1295 in these assays are in the low nanomolar range, similar to those of native GHRH(1-29), confirming that the DAC modification does not impair receptor binding affinity at the GHRHR binding pocket.
GH Pulse Pattern: Extended Action vs. Short-Acting GHRH Analogues
One of the primary research questions surrounding CJC-1295 concerns how its extended pharmacokinetics alter the pattern of GH release compared to short-acting GHRH analogues. Physiological GH secretion is characteristically pulsatile — discrete bursts of GH separated by near-baseline inter-pulse intervals. This pulsatility is important for downstream IGF-1 signaling and is regulated by the interplay between hypothalamic GHRH (stimulatory) and somatostatin (inhibitory).
Short-acting GHRH analogues such as sermorelin have a pharmacokinetic profile closer to native GHRH: they stimulate a discrete GH pulse and are then cleared, allowing somatostatin to re-establish inter-pulse baseline. In contrast, CJC-1295 (DAC), by maintaining sustained GHRHR occupancy over days rather than hours, alters this dynamic. Research using animal pituitary models has investigated whether sustained GHRHR activation drives a maintained GH secretory state or whether the feedback loop — particularly somatostatin up-regulation in response to GH and IGF-1 — ultimately blunts the response, modulating the degree of sustained elevation.
This distinction is relevant to research designs in which pulsatility per se is the experimental variable. Researchers comparing CJC-1295 (DAC) to sermorelin or non-DAC GHRH(1-29) can use the contrast to probe somatotroph feedback sensitivity, receptor desensitization kinetics, and the downstream IGF-1 axis response to different temporal patterns of GHRHR activation.
Comparison with Sermorelin and Non-DAC GHRH Analogues
The research landscape of GHRH analogues provides a useful comparative framework for understanding CJC-1295's distinctive profile:
- Native GHRH(1-44) — full-length endogenous peptide; rapidly degraded by DPP-IV; half-life of 2–5 minutes in physiological models
- Sermorelin / GHRH(1-29) — shortest synthetic GHRH analogue retaining full receptor activity; similarly short half-life; used where pulse-mimicking pharmacokinetics are desired; no DAC modification
- CJC-1295 without DAC (MOD-GRF 1-29) — incorporates amino acid substitutions at DPP-IV cleavage sites (typically Ala2 replaced by Aib) to resist enzymatic degradation, extending half-life to approximately 30 minutes in rodent plasma models; no albumin conjugation
- CJC-1295 (DAC) — adds the MPA/albumin-binding mechanism on top of DPP-IV resistance; half-life in the range of days; provides a sustained, depot-like release profile suitable for extended time-course studies
This spectrum of analogues allows researchers to modulate half-life as an independent experimental variable while holding receptor binding and downstream signal transduction largely constant — a powerful tool for dissecting how the temporal dynamics of GHRHR activation shape somatotroph biology.
Research Applications in Pituitary Biology
CJC-1295 is used in several specific research contexts enabled by its extended-action profile. Longitudinal studies examining somatotroph cell biology over days to weeks benefit from the reduced dosing frequency compared to short-acting analogues. Receptor desensitization studies compare GH secretory responses after repeated pulsed dosing (sermorelin model) versus sustained occupancy (CJC-1295 DAC model) to characterize GHRHR down-regulation kinetics. IGF-1 axis research in cell culture and organoid systems uses CJC-1295 to maintain sustained GH output as a driver of IGF-1 production, enabling longer-window studies of downstream signaling without requiring frequent compound additions.
In all such applications, CJC-1295 serves as a pharmacological tool — its value lies in its precisely characterized DAC mechanism and the well-defined contrast it provides against shorter-acting GHRH analogues in the same experimental panel.